



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: July 3, 2019

The Manager  
Dept. of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001  
**Script Code: 540596**

The Asst Vice President  
Listing Department  
National Stock Exchange of India  
Limited  
Exchange Plaza, C-1, Block G  
Bandra – Kurla Complex,  
Mumbai 400051  
**Symbol: ERIS**

Dear Sir,

**Sub: Outcome of the meeting of the Board of Directors of Eris Lifesciences Limited (Company) held today, i.e. on July 3, 2019**

Pursuant to Regulation 30 of the Listing Regulations and other applicable provisions of law, we wish to inform you that, the Board of Directors of the Company at its meeting held today, i.e. July 3, 2019 has inter-alia:

1. Approved buyback proposal for purchase by the Company of its own fully paid equity shares of Re. 1 each (Equity Share) up to 17,39,130 Equity Shares (being ~1.26% of the total paid-up equity capital of the Company) at a price of Rs. 575/- (Rupees Five hundred seventy five only) per Equity Share, for a maximum aggregate consideration not exceeding Rs. 100 crore (Rupees One hundred crore Only) [excluding any expenses incurred or to be incurred for the Buyback like filing fees payable to the Securities and Exchange Board of India, if any, brokerage, applicable taxes (such as securities transaction tax, stamp duty and goods and service tax), advisors' fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses], being less than 25% of the aggregate paid-up equity share capital and free reserves (including securities premium account) of the Company as on March 31, 2019 (hereinafter referred to as the Buyback) from the shareholders of the Company on a proportionate basis through the tender offer route in accordance and consonance with the provisions contained in the Companies Act, 2013 and the Securities and Exchange Board of India (Buy Back of Securities) Regulations, 2018 (Buyback Regulation) (including any statutory modification(s) or re-enactment of the Companies Act, 2013 or Buyback Regulation). The public announcement setting out the process, timelines and other statutory details will be released in due course in accordance with the Buyback Regulation. The Board has designated the Executive Committee to act as Buyback and Executive Committee (the "Buyback Committee / Committee") and has delegated its powers to the Buyback Committee to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, usual or proper in connection with the Buyback. The pre-Buyback shareholding pattern of the Company as on June 28, 2019 is attached hereto as Annexure A and the post Buy-Back shareholding pattern and actual securities bought back (in number and percentage) of the existing paid up capital will be provided on completion of the Buy-Back.

Registered & Corporate Office:

8<sup>th</sup> Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



EY Entrepreneur  
of the year-2013



FROST & SULLIVAN  
Best Practices-2013



Business today/YES bank  
Excellence Awards-2013



2. Noted that the Promoters and Promoter Group of the Company have expressed their intention to not participate in the Buyback.

3. Fixed Monday, July 15, 2019 as the Record Date for the purpose of determining the entitlement and the names of equity shareholders who are eligible to participate in the Buyback.

4. Extended the relieving date of Mr. Himanshu Shah as Whole Time Director, with his due consent, from 16th July, 2019 to 30th September, 2019.

The meeting of the Board of Directors commenced at 11:15 a.m. and closed at 12:55 p.m.

This above is for your information and record please.

Thanking you,

Yours faithfully,

**For Eris Lifesciences Limited**

**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**

**Encl: As above**

**Registered & Corporate Office:**

8<sup>th</sup> Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



## Annexure A

Pre Buyback Shareholding pattern of Eris Lifesciences Limited as on June 28, 2019:

Particulars	Number of Shares	% to the existing Equity Share capital
Promoters and Promoter Group	77331807	56.23
Mutual Funds/Alternative Investment Funds/Financial Institutional/Banks	16112081	11.72
Foreign Portfolio Investors	10895551	7.92
Public/Clearing members/HUF/Trusts/ Independent Director/ NBFCs registered with RBI/ Other Bodies Corporate	32978707	23.98
Non Resident Indians (Repatriable and Non Repatriable)	201637	0.15
<b>Total</b>	<b>137519783</b>	<b>100.00</b>

**Registered & Corporate Office:**

8<sup>th</sup> Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867